Category:

Zogenix’s FINTEPLA® (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome gets FDA Approval

Zogenix’s FINTEPLA (fenfluramine), an oral solution CIV for the Treatment of Seizures Associated with Dravet Syndrome in patients aged 2 years and above gets approval from the U.S. Food and Drug Administration (FDA). Dravet syndrome is a childhood-onset epilepsy which occurs mostly after frequent and severe treatment-resistant seizures during the hospitalizations and medical emergencies, number Continue Reading

Posted On :